D.A.P. Revises HIV Prevention Guidelines

Desert AIDS Project revises its prevention guidelines in light of support for new research

CONTINUE READING

D.A.P. tests new treatment for drug-resistant STI

Desert AIDS Project is studying a new treatment for a very pervasive sexually-transmitted infection (STI) that’s now become drug-resistant. Under the direction of Dr. Steven Scheibel, D.A.P. is studying the efficacy, safety, and side effects of a drug that combats Nesseria gonorrhoeae, the bacteria that causes gonorrhea. Gonorrhea is the second most common STI and […]

CONTINUE READING

Can we ease strain of HIV meds on bones and kidneys?

Desert AIDS Project is participating in a study designed to test a drug that suppresses the HIV infection without threatening bone mass and kidney functions. The name of the study is a mouthful. It’s called, “A Phase 3b Double-Blind, Randomized, Switch Study to Evaluate F/TAF in HIV-1 Infected Subjects who are Viralogically Suppressed on Regimens […]

CONTINUE READING

Exciting breakthrough in treating dysplasia

Dr. Steven Scheibel, Medical Director at Desert AIDS Project, believes he’s found a new way to treat the conditions that can lead to anal cancer. The new therapy uses human papillomavirus (HPV) vaccines in conjunction with an immune-boosting cream to kill anal dysplasia, which is often a gateway to anal cancer. This therapy promises to […]

CONTINUE READING
International Conference on AIDS

Triple-90 means the end of AIDS

The biennial conference of AIDS specialists hailed dramatic progress in treatment and promoted the notion that the AIDS pandemic can end by 2030. The International AIDS Society met from July 19 to July 22 in Vancouver, Canada. They called early treatment, prophylactic drugs, and wide-spread testing that makes everyone aware of their HIV status central […]

CONTINUE READING

Study confirms early treatment is best

A major international study has found that HIV-infected individuals have a considerably lower risk of developing AIDS or other serious illnesses if they start taking antiretroviral drugs sooner rather than later. The Strategic Timing of AntiRetroviral Treatment study, (START), indicates that patients have better outcomes when they begin medicating when their CD4+ T-cell count—a key […]

CONTINUE READING

Medication Therapy Management study seeks to improve Patient-Centered HIV Care

About two years ago, Walgreens and the Centers for Disease Control and Prevention (CDC) put together a model for pharmacies that cater to HIV patients aptly called the Patient-Centered HIV Care Model. Its objective: To improve the outcomes of people living with HIV by making direct connections between the patient’s doctor and their pharmacist. To […]

CONTINUE READING

Building Research Capacity in Aging HIV-infected Persons

Many patients with HIV disease are aging. By the year 2015, approximately 70% of HIV patient will be over 50 years old.  With HIV and aging there is an increased incidence of co-morbid conditions such as coronary artery disease, diabetes, high cholesterol and hypertension.  Also, there is a higher incidence of HIV associated neurocognitive decline […]

CONTINUE READING
Change this in Theme Options
Change this in Theme Options